PMC:7228307 / 44412-44530 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"802","span":{"begin":78,"end":85},"obj":"Gene"},{"id":"842","span":{"begin":44,"end":49},"obj":"Mutation"},{"id":"843","span":{"begin":51,"end":56},"obj":"Mutation"}],"attributes":[{"id":"A802","pred":"tao:has_database_id","subj":"802","obj":"Gene:2214"},{"id":"A842","pred":"tao:has_standard_notation","subj":"842","obj":"p.S239D"},{"id":"A843","pred":"tao:has_standard_notation","subj":"843","obj":"p.I332E"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T787","span":{"begin":32,"end":36},"obj":"http://purl.obolibrary.org/obo/CLO_0053432"},{"id":"T788","span":{"begin":78,"end":80},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"802","span":{"begin":78,"end":85},"obj":"Gene"},{"id":"842","span":{"begin":44,"end":49},"obj":"Mutation"},{"id":"843","span":{"begin":51,"end":56},"obj":"Mutation"}],"attributes":[{"id":"A802","pred":"pubann:denotes","subj":"802","obj":"Gene:2214"},{"id":"A842","pred":"pubann:has_HGVS_notation","subj":"842","obj":"p.S239D"},{"id":"A843","pred":"pubann:has_HGVS_notation","subj":"843","obj":"p.I332E"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T254","span":{"begin":0,"end":118},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T514","span":{"begin":32,"end":36},"obj":"Protein"}],"attributes":[{"id":"A514","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/Q9BRD6"},{"id":"A515","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/Q96S68"},{"id":"A516","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/Q542B2"},{"id":"A517","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/Q3LRP3"},{"id":"A518","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/P25918"},{"id":"A519","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/P25917"},{"id":"A520","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/P15391"},{"id":"A521","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/F5H635"},{"id":"A522","pred":"uniprot_id","subj":"T514","obj":"https://www.uniprot.org/uniprot/A0N0P9"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T23","span":{"begin":99,"end":107},"obj":"Phenotype"}],"attributes":[{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-sentences","denotations":[{"id":"T254","span":{"begin":0,"end":118},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T23","span":{"begin":99,"end":107},"obj":"Phenotype"}],"attributes":[{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III"}